12 September 2025 in Journal of Open Source Software
Package provides a flexible and efficient way to create synthetic datasets in OMOP CDM format, facilitating the testing and validation of packages and analytic codes.
17 November 2025 in medRxiv
Background: Real-world data are valuable for detecting adverse drug events, and Sequence Symmetry Analysis (SSA) is a simple yet effective method frequently used for this purpose. However, heterogeneous implementations across studies limit reproducibility and scalability. To address this, we developed an open-source R package that standardises SSA analytics using data mapped to the Observational Medical Outcomes Partnership (OMOP) Common Data Model (CDM). Methods: We developed CohortSymmetry , an R package that implements SSA for OMOP CDM data. The package was validated through unit testing and evaluated empirically by estimating adjusted sequence ratios (ASRs) with 95% confidence intervals (CIs) for 23 positive and 10 negative controls across six European databases, including CPRD GOLD (UK) and THIN® (Belgium, Italy, Romania, Spain, UK). Sensitivity and specificity were defined as the proportions of positive and negative controls correctly identified by SSA. Sensitivity analyses varied key parameters, including the washout period. Results: CohortSymmetry passed high-coverage unit tests. Of 33 eligible controls, four showed results consistent with expectations across all databases; for example, the amiodarone–levothyroxine pair had a lower 95% CI bound >1 in each. Sensitivity was moderate, whereas specificity was high in the primary analyses. Parameter variation influenced outcomes; a 365-day prior observation requirement reduced specificity in CPRD GOLD from 75% to 38%. Conclusions: CohortSymmetry enables reproducible SSA using OMOP CDM data. Differences across databases likely reflect heterogeneity in data capture and prescribing patterns. Limitations include residual data variability and SSA’s susceptibility to time-varying confounding, underscoring the need for tailored analytic design in pharmacovigilance studies. Key Messages: We developed CohortSymmetry, an open-source R package that standardises SSA analytics using OMOP CDM-mapped data and verified the correctness of functions via unit testing and application to real-world datasets. CohortSymmetry passed high-coverage tests, and among 33 selected controls, four showed results consistent with expectations across all databases; varying analytical parameters affected results. The package provides a reproducible and scalable framework for multi-database SSA studies, supporting robust pharmacovigilance, but careful specification of parameters is required to account for the characteristics of the medical domain under investigation.